Novartis Stock Price, News & Analysis (NYSE:NVS)

$84.66 0.20 (0.24 %)
(As of 12/14/2017 01:03 AM ET)
Previous Close$84.46
Today's Range$84.46 - $85.10
52-Week Range$69.53 - $86.90
Volume879,300 shs
Average Volume2.25 million shs
Market Capitalization$220.99 billion
P/E Ratio17.64
Dividend Yield2.75%
Beta0.73

About Novartis (NYSE:NVS)

Novartis logoNovartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:NVS
CUSIPN/A
Phone+41-61-3241111

Debt

Debt-to-Equity Ratio0.32%
Current Ratio1.08%
Quick Ratio0.81%

Price-To-Earnings

Trailing P/E Ratio17.64
Forward P/E Ratio17.82
P/E Growth2.66

Sales & Book Value

Annual Sales$48.52 billion
Price / Sales4.13
Cash Flow$4.82 per share
Price / Cash17.58
Book Value$31.55 per share
Price / Book2.68

Profitability

Trailing EPS$2.81
Net Income$6.71 billion
Net Margins13.73%
Return on Equity15.77%
Return on Assets8.46%

Miscellaneous

Employees123,000
Outstanding Shares2,365,590,000

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis declared an annual dividend on Friday, January 27th. Shareholders of record on Friday, March 3rd will be paid a dividend of $2.327 per share on Friday, March 3rd. The ex-dividend date is Wednesday, March 1st. View Novartis' Dividend History.

How will Novartis' stock buyback program work?

Novartis declared that its Board of Directors has authorized a stock buyback program on Saturday, April 8th 2017, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 2.9% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its earnings results on Tuesday, October, 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.25 by $0.04. The firm earned $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis's revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.23 earnings per share. View Novartis' Earnings History.

When will Novartis make its next earnings announcement?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for Novartis.

Where is Novartis' stock going? Where will Novartis' stock price be in 2017?

14 brokers have issued 12 month price objectives for Novartis' stock. Their predictions range from $74.37 to $91.00. On average, they expect Novartis' share price to reach $84.41 in the next year. View Analyst Ratings for Novartis.

Are investors shorting Novartis?

Novartis saw a increase in short interest in November. As of November 30th, there was short interest totalling 2,783,787 shares, an increase of 41.2% from the November 15th total of 1,971,173 shares. Based on an average trading volume of 1,506,535 shares, the short-interest ratio is presently 1.8 days.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee (Age 57)
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee (Age 51)
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee (Age 48)
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee (Age 60)
  • Steven Baert, Head of Human Resources, Member of the Executive Committee (Age 42)
  • Vasant Narasimhan M.D., Chief Executive Officer, Member of the Executive Committee

Who owns Novartis stock?

Novartis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Parnassus Investments CA (0.40%), Fisher Asset Management LLC (0.25%), Manning & Napier Advisors LLC (0.19%), Mawer Investment Management Ltd. (0.11%), Earnest Partners LLC (0.08%) and Janus Henderson Group PLC (0.08%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Who sold Novartis stock? Who is selling Novartis stock?

Novartis' stock was sold by a variety of institutional investors in the last quarter, including Sei Investments Co., Manning & Napier Advisors LLC, Sectoral Asset Management Inc, Dimensional Fund Advisors LP, Assetmark Inc., Private Asset Management Inc., Tdam USA Inc. and First Republic Investment Management Inc.. View Insider Buying and Selling for Novartis.

Who bought Novartis stock? Who is buying Novartis stock?

Novartis' stock was purchased by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Boston Partners, Amundi Pioneer Asset Management Inc., Russell Investments Group Ltd., Crossmark Global Holdings Inc., Fisher Asset Management LLC, Principal Financial Group Inc. and Seatown Holdings Pte. Ltd.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy Novartis stock?

Shares of Novartis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of Novartis stock can currently be purchased for approximately $84.66.

How big of a company is Novartis?

Novartis has a market capitalization of $220.99 billion and generates $48.52 billion in revenue each year. The company earns $6.71 billion in net income (profit) each year or $2.81 on an earnings per share basis. Novartis employs 123,000 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  284 (Vote Outperform)
Underperform Votes:  340 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (NYSE:NVS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.132.182.242.12
Ratings Breakdown: 4 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
9 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $85.77$85.77$84.44$84.23
Price Target Upside: 2.30% upside4.93% upside0.75% upside4.70% upside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2017Bank of AmericaDowngradeNeutral -> UnderperformLowView Rating Details
10/31/2017J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
10/25/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 -> $91.00N/AView Rating Details
8/9/2017CowenSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
3/22/2017Goldman Sachs GroupReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Deutsche BankReiterated RatingNeutralN/AView Rating Details
10/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
5/24/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018        
10/24/20179/30/2017$1.25$1.29$12.21 billion$12.41 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.20 billion$12.24 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.59 billion$11.54 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.44 billion$12.32 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.13 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.94 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.83 billion$14.64 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.25 billion$14.02 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.08 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.02 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Novartis (NYSE:NVS) Earnings Estimates

2017 EPS Consensus Estimate: $4.72
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.08$1.15$1.12
Q2 20172$1.15$1.22$1.19
Q3 20172$1.24$1.25$1.25
Q4 20171$1.17$1.17$1.17
(Data provided by Zacks Investment Research)

Dividends

Novartis (NYSE:NVS) Dividend Information

Most Recent Dividend:3/3/2017
Annual Dividend:$2.30
Dividend Yield:2.72%
Dividend Growth:3.90% (3 Year Average)
Payout Ratio:81.85% (Trailing 12 Months of Earnings)
48.42% (Based on This Year's Estimates)
45.19% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.333/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.723.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.87%
Insider Trades by Quarter for Novartis (NYSE:NVS)
Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More - BenzingaASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More - Benzinga
www.benzinga.com - December 13 at 4:47 PM
Health Care Sector Update for 12/13/2017: NVS,IOVA,RSLS - NasdaqHealth Care Sector Update for 12/13/2017: NVS,IOVA,RSLS - Nasdaq
www.nasdaq.com - December 13 at 4:47 PM
Novartis generics arm says may sell or end some productsNovartis generics arm says may sell or end some products
finance.yahoo.com - December 13 at 10:40 AM
Form 8-K PROTEOSTASIS THERAPEUTIC For: Dec 05Form 8-K PROTEOSTASIS THERAPEUTIC For: Dec 05
www.streetinsider.com - December 12 at 4:55 PM
Novartis Reports Updated Results from Kymriahs JULIET Study - NasdaqNovartis Reports Updated Results from Kymriah's JULIET Study - Nasdaq
www.nasdaq.com - December 12 at 10:45 AM
These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018These defensive stocks make the cut as one of Morgan Stanley’s key picks for 2018
finance.yahoo.com - December 11 at 4:47 PM
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed TodayHere's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
finance.yahoo.com - December 11 at 4:47 PM
Novartis CAR-T therapy leads to durable response in lymphoma studyNovartis CAR-T therapy leads to durable response in lymphoma study
finance.yahoo.com - December 10 at 4:48 PM
Novartis AG (NVS) a Buy on High-Level Quant Score - Investorplace.comNovartis AG (NVS) a Buy on High-Level Quant Score - Investorplace.com
www.investorplace.com - December 8 at 4:33 PM
Pfizer Reports Updated Data from Phase III Study on IbrancePfizer Reports Updated Data from Phase III Study on Ibrance
finance.yahoo.com - December 7 at 4:54 PM
Novartis Commences Cash Tender Offer To Buy Advanced Accelerator ApplicationsNovartis Commences Cash Tender Offer To Buy Advanced Accelerator Applications
www.nasdaq.com - December 7 at 10:41 AM
In Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves SymptomsIn Young Women With Metastatic Breast Cancer, Kisqali Delays Tumor Growth And Relieves Symptoms
finance.yahoo.com - December 7 at 10:41 AM
Novartis (NVS) Rating Lowered to Underperform at Bank of AmericaNovartis (NVS) Rating Lowered to Underperform at Bank of America
www.americanbankingnews.com - December 6 at 9:20 PM
Advanced Accelerator Applications (AAAP) Board of Directors Backs $3.9 Billion All Cash Tender Offer by Novartis (NVS) - StreetInsider.comAdvanced Accelerator Applications (AAAP) Board of Directors Backs $3.9 Billion All Cash Tender Offer by Novartis (NVS) - StreetInsider.com
www.streetinsider.com - December 6 at 10:35 AM
Advanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by NovartisAdvanced Accelerator Applications Board of Directors Recommends $3.9 Billion All Cash Tender Offer by Novartis
finance.yahoo.com - December 5 at 4:33 PM
Behind Novartis’s Developments as of November 2017Behind Novartis’s Developments as of November 2017
finance.yahoo.com - December 4 at 4:37 PM
Inside Novartis’s Alcon Performance in 3Q17Inside Novartis’s Alcon Performance in 3Q17
finance.yahoo.com - December 4 at 10:18 AM
Opportunity flows when it comes to Swiss stocksOpportunity flows when it comes to Swiss stocks
finance.yahoo.com - December 2 at 4:31 PM
Novartis AG (NVS) Given Consensus Rating of "Hold" by AnalystsNovartis AG (NVS) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - December 1 at 9:48 PM
Inside Novartis’s Innovative Medicines Business in 3Q17Inside Novartis’s Innovative Medicines Business in 3Q17
finance.yahoo.com - December 1 at 5:36 PM
Head to Head Analysis: Novartis (NVS) vs. Its CompetitorsHead to Head Analysis: Novartis (NVS) vs. Its Competitors
www.americanbankingnews.com - November 28 at 9:08 PM
Pharmas Paradox: Cure A Deadly Childhood Disease And Then Get Attacked On PricePharma's Paradox: Cure A Deadly Childhood Disease And Then Get Attacked On Price
finance.yahoo.com - November 28 at 4:34 PM
Will New Drug Approvals Boost Novartis (NVS) Portfolio? - NasdaqWill New Drug Approvals Boost Novartis (NVS) Portfolio? - Nasdaq
www.nasdaq.com - November 25 at 9:21 AM
Novartis AG (NVS) a Buy on Solid Earnings Visibility - Investorplace.comNovartis AG (NVS) a Buy on Solid Earnings Visibility - Investorplace.com
investorplace.com - November 25 at 9:21 AM
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents DataPharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data
finance.yahoo.com - November 24 at 9:19 AM
Novartis AG (NVS) a Buy on Solid Earnings VisibilityNovartis AG (NVS) a Buy on Solid Earnings Visibility
investorplace.com - November 24 at 8:51 AM
Novartis (NVS) Receives EC Nod for Tasigna Label Expansion ... - NasdaqNovartis (NVS) Receives EC Nod for Tasigna Label Expansion ... - Nasdaq
www.nasdaq.com - November 23 at 7:03 AM
Contrasting Novartis AG (NVS) & Its CompetitorsContrasting Novartis AG (NVS) & Its Competitors
www.americanbankingnews.com - November 20 at 1:30 AM
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy - Investorplace.comImproving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy - Investorplace.com
investorplace.com - November 19 at 2:59 AM
Novartis AG (NVS) versus Cambrex Corporation (CBM) Head to Head SurveyNovartis AG (NVS) versus Cambrex Corporation (CBM) Head to Head Survey
www.americanbankingnews.com - November 18 at 11:14 AM
How Novartis’s Tasigna Is Looking NowHow Novartis’s Tasigna Is Looking Now
finance.yahoo.com - November 18 at 9:23 AM
Behind 4 Key Novartis Money Makers (and Losers) in 3Q17Behind 4 Key Novartis Money Makers (and Losers) in 3Q17
finance.yahoo.com - November 18 at 9:23 AM
CMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare SummitCMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare Summit
finance.yahoo.com - November 18 at 9:23 AM
How 2 Key Novartis Oncology Drugs Performed in 3Q17How 2 Key Novartis Oncology Drugs Performed in 3Q17
finance.yahoo.com - November 18 at 9:23 AM
How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?
finance.yahoo.com - November 18 at 9:23 AM
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to BuyImproving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy
investorplace.com - November 17 at 12:21 PM
Novartis (NVS) Arms Biosimilars Study Results Encourage - NasdaqNovartis (NVS) Arm's Biosimilars Study Results Encourage - Nasdaq
www.nasdaq.com - November 15 at 6:56 AM
Novartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III TrialNovartis: Canakinumab Reduces Cardiovascular Risk In CANTOS Phase III Trial
www.finanznachrichten.de - November 14 at 6:17 AM
Novartis launches heart drug counter-offensiveNovartis launches heart drug counter-offensive
finance.yahoo.com - November 14 at 6:17 AM
Novartis posts eye drug data amid play for Eyleas turfNovartis posts eye drug data amid play for Eylea's turf
finance.yahoo.com - November 12 at 11:07 AM
Better Buy: Exelixis, Inc. vs. Novartis AGBetter Buy: Exelixis, Inc. vs. Novartis AG
finance.yahoo.com - November 12 at 11:07 AM
Solid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to BuySolid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to Buy
investorplace.com - November 10 at 9:27 AM
Comparing Novartis AG (NVS) & Its RivalsComparing Novartis AG (NVS) & Its Rivals
www.americanbankingnews.com - November 9 at 10:27 AM
Novartis takes fight to Pfizers Ibrance with new Kisqali dataNovartis takes fight to Pfizer's Ibrance with new Kisqali data
finance.yahoo.com - November 9 at 7:51 AM
Novartis: MONALEESA-7 Trial Meets Primary Endpoint Of Progression-free Survival - NasdaqNovartis: MONALEESA-7 Trial Meets Primary Endpoint Of Progression-free Survival - Nasdaq
www.nasdaq.com - November 8 at 2:46 AM
Novartis: Cosentyx Reduced Signs Of Psoriatic Arthritis In Future 5 StudyNovartis: Cosentyx Reduced Signs Of Psoriatic Arthritis In Future 5 Study
www.rttnews.com - November 7 at 4:30 PM
ETFs with exposure to Novartis AG : November 6, 2017ETFs with exposure to Novartis AG : November 6, 2017
finance.yahoo.com - November 7 at 4:30 PM
Here's Why Advanced Accelerator Application SA Rose 20% in OctoberHere's Why Advanced Accelerator Application SA Rose 20% in October
finance.yahoo.com - November 7 at 4:29 PM
Novartis AG (NVS) Receives Consensus Rating of "Hold" from BrokeragesNovartis AG (NVS) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 6 at 5:48 PM
Novartis, Amgen Report Expanded Collaboration With Banner Alzheimers InstituteNovartis, Amgen Report Expanded Collaboration With Banner Alzheimer's Institute
www.finanznachrichten.de - November 4 at 4:01 PM

SEC Filings

Novartis (NYSE:NVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novartis (NYSE NVS) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.